BIOHAVEN PHARMACEUTICAL HOLDING CO LTD
NYSE: BHVN (Biohaven Ltd.)
Last update: 8 hours ago36.26
0.92 (2.60%)
| Previous Close | 35.34 |
| Open | 34.85 |
| Volume | 2,580,291 |
| Avg. Volume (3M) | 1,079,892 |
| Market Cap | 3,666,683,648 |
| Price / Book | 11.75 |
| 52 Weeks Range | |
| Earnings Date | 3 Aug 2023 - 7 Aug 2023 |
| Diluted EPS (TTM) | -9.37 |
| Total Debt/Equity (MRQ) | 8.01% |
| Current Ratio (MRQ) | 2.89 |
| Operating Cash Flow (TTM) | -526.59 M |
| Levered Free Cash Flow (TTM) | -397.26 M |
| Return on Assets (TTM) | -118.79% |
| Return on Equity (TTM) | -265.45% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Biohaven Ltd. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 2.50 |
|
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 11.16% |
| % Held by Institutions | 87.14% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Suvretta Capital Management, Llc | 30 Sep 2024 | 5,199,219 |
| Bellevue Group Ag | 30 Sep 2024 | 2,040,853 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 76.00 (Piper Sandler, 109.60%) | Buy |
| Median | 62.00 (70.99%) | |
| Low | 59.00 (HC Wainwright & Co., 62.71%) | Buy |
| Average | 65.22 (79.87%) | |
| Total | 9 Buy | |
| Avg. Price @ Call | 45.42 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 17 Dec 2024 | 59.00 (62.71%) | Buy | 39.12 |
| 26 Nov 2024 | 59.00 (62.71%) | Buy | 47.28 | |
| RBC Capital | 04 Dec 2024 | 61.00 (68.23%) | Buy | 46.06 |
| 25 Nov 2024 | 58.00 (59.96%) | Buy | 45.23 | |
| TD Cowen | 13 Nov 2024 | 75.00 (106.84%) | Buy | 49.04 |
| JP Morgan | 03 Oct 2024 | 68.00 (87.53%) | Buy | 46.65 |
| B of A Securities | 24 Sep 2024 | 62.00 (70.99%) | Buy | 45.04 |
| Bernstein | 24 Sep 2024 | 66.00 (82.02%) | Buy | 45.04 |
| Baird | 23 Sep 2024 | 60.00 (65.47%) | Buy | 45.94 |
| Leerink Partners | 23 Sep 2024 | 60.00 (65.47%) | Buy | 45.94 |
| Piper Sandler | 23 Sep 2024 | 76.00 (109.60%) | Buy | 45.94 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |